Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of Losartan
potassium/Hydrochlorothiazide 100/25 mg tablets (manufactured by Teva Pharmaceutical
Industries, Ltd. and distributed by Teva Pharmaceuticals USA) with that of Hyzaar® 100/25 mg
tablets (Merck) in healthy, adult, non-smoking subjects under non-fasting conditions.